Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| 1 |
NVIDIA
NVDA
|
+$307M |
| 2 |
Mercado Libre
MELI
|
+$289M |
| 3 |
Atlassian
TEAM
|
+$283M |
| 4 |
Shopify
SHOP
|
+$275M |
| 5 |
Roblox
RBLX
|
+$243M |
Top Sells
| 1 |
ABMD
Abiomed Inc
ABMD
|
+$1.38B |
| 2 |
Meta Platforms (Facebook)
META
|
+$565M |
| 3 |
Illumina
ILMN
|
+$460M |
| 4 |
Ferrari
RACE
|
+$328M |
| 5 |
Arthur J. Gallagher & Co
AJG
|
+$296M |
Sector Composition
| 1 | Healthcare | 27.94% |
| 2 | Consumer Discretionary | 24.47% |
| 3 | Technology | 18.46% |
| 4 | Communication Services | 10.28% |
| 5 | Financials | 7.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELL
251
DELISTED
PhenomeX Inc. Common Stock
CELL
| $3.61M | ﹤0.01% |
1,347,301
-2,370,899
| -64% | -$6.35M |
|
252
Alector
ALEC
$279M
| $3.56M | ﹤0.01% |
385,957
+14,120
| +4% | +$130K |
|
253
Allbirds
BIRD
$49.4M
| $3.31M | ﹤0.01% |
68,404
| – | – |
|
|
API
254
Agora
API
$334M
| $2.91M | ﹤0.01% |
744,300
| – | – |
|
255
GitLab
GTLB
$7.99B
| $2.85M | ﹤0.01% |
62,613
-1,970
| -3% | -$89.5K |
|
256
Oscar Health
OSCR
$5.24B
| $2.71M | ﹤0.01% |
1,100,079
-19,268,409
| -95% | -$47.4M |
|
257
Lyell Immunopharma
LYEL
$250M
| $2.64M | ﹤0.01% |
38,066
+311
| +0.8% | +$21.6K |
|
258
Clover Health Investments
CLOV
$1.4B
| $2.46M | ﹤0.01% |
2,645,503
| – | – |
|
|
NCNA
259
NuCana
NCNA
$5.51M
| $2.41M | ﹤0.01% |
732
| – | – |
|
|
MTLS
260
Materialise
MTLS
$307M
| $2.36M | ﹤0.01% |
268,000
| – | – |
|
261
HUTCHMED
HCM
$2.74B
| $2.25M | ﹤0.01% |
152,225
-237,593
| -61% | -$3.51M |
|
262
Floor & Decor
FND
$9.45B
| $2.14M | ﹤0.01% |
+30,696
| New | +$2.14M |
|
263
Adicet Bio
ACET
$63.5M
| $1.62M | ﹤0.01% |
181,626
| – | – |
|
264
Golub Capital BDC
GBDC
$3.93B
| $1.61M | ﹤0.01% |
122,100
| – | – |
|
265
MaxCyte
MXCT
$150M
| $1.54M | ﹤0.01% |
293,325
+90,525
| +45% | +$476K |
|
266
Sixth Street Specialty
TSLX
$2.32B
| $1.42M | ﹤0.01% |
79,500
| – | – |
|
267
Agnico Eagle Mines
AEM
$77.5B
| $1.37M | ﹤0.01% |
26,423
| – | – |
|
|
CLLS
268
Cellectis
CLLS
$275M
| $1.26M | ﹤0.01% |
599,896
-188,941
| -24% | -$397K |
|
269
Newmont
NEM
$83.2B
| $1.23M | ﹤0.01% |
25,959
| – | – |
|
|
ABMD
270
DELISTED
Abiomed Inc
ABMD
| $1.14M | ﹤0.01% |
2,991
-3,621,946
| -100% | -$1.38B |
|
271
Novanta
NOVT
$4.16B
| $1.08M | ﹤0.01% |
7,938
| – | – |
|
272
WEC Energy
WEC
$34.6B
| $1.06M | ﹤0.01% |
11,353
| – | – |
|
273
Ameren
AEE
$27B
| $1.05M | ﹤0.01% |
11,802
+1,412
| +14% | +$126K |
|
274
Exelon
EXC
$43.4B
| $988K | ﹤0.01% |
22,861
| – | – |
|
275
Fortis
FTS
$24.6B
| $956K | ﹤0.01% |
23,917
+2,927
| +14% | +$117K |
|